EP0870191A1 - Membranes biocompatibles contenant des silicones - Google Patents

Membranes biocompatibles contenant des silicones

Info

Publication number
EP0870191A1
EP0870191A1 EP96933898A EP96933898A EP0870191A1 EP 0870191 A1 EP0870191 A1 EP 0870191A1 EP 96933898 A EP96933898 A EP 96933898A EP 96933898 A EP96933898 A EP 96933898A EP 0870191 A1 EP0870191 A1 EP 0870191A1
Authority
EP
European Patent Office
Prior art keywords
diisocyanate
glucose
membrane
polymer
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96933898A
Other languages
German (de)
English (en)
Inventor
Bill Van Antwerp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medtronic Minimed Inc
Original Assignee
Minimed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minimed Inc filed Critical Minimed Inc
Priority claimed from CA002238005A external-priority patent/CA2238005C/fr
Publication of EP0870191A1 publication Critical patent/EP0870191A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
    • C08G18/40—High-molecular-weight compounds
    • C08G18/61—Polysiloxanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
    • C08G18/40—High-molecular-weight compounds
    • C08G18/48—Polyethers
    • C08G18/4833—Polyethers containing oxyethylene units
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/001—Enzyme electrodes
    • C12Q1/002—Electrode membranes

Definitions

  • This invention lies in the field of polymer chemistry in which the polymers produced can be formed into membranes suitable for in vivo use.
  • Biosensors are small devices that use biological recognition properties for selective analysis of various analytes or biomolecules. Typically, the sensor will produce a signal that is quantitatively related to the concentration of the analyte. To achieve a quantitative signal, a recognition molecule or combination of molecules is often immobilized at a suitable transducer which converts the biological recognition event into a quantitative response.
  • Biosensors have been developed for use with numerous analytes. Electroenzymatic biosensors use enzymes to convert a concentration of analyte to an electrical signal. Immunological biosensors rely on molecular recognition of an analyte by, for example, antibodies. Chemoreceptor biosensors use chemoreceptor arrays such as those of the olfactory system or nerve fibers from the antennules of the blue crab Callinectes sapidus to detect the presence of amino acids in concentrations as low as 10 "9 M. For a review of some of the operating principles of biosensors, see Berg veld, et al, ADVANCES IN BIOSENSORS, Supplement 1 , p. 31-91, Turner ed. , and Collison, et al., Anal. Chem. 62:425-437 (1990).
  • each must possess certain properties to function in vivo and provide an adequate signal.
  • the elements of the biosensor must be compatible with the tissue to which it is attached and be adequately shielded from adjacent tissues such that allergic or toxic effects are not exerted.
  • the sensor should be shielded from the environment to control drift in the generated signal.
  • the sensor should accurately measure the analyte in the presence of proteins, electrolytes and medications which may interfere.
  • the prototype biosensor is the amperometric glucose sensor.
  • glucose sensors are useful for glucose monitoring of patients with diabetes mellitus.
  • a working glucose sensor is required for the development of a closed loop artificial pancreas with an implanted insulin pump.
  • a commercial interest focuses on sensors that can be used to monitor fermentation reactions in the biotechnology arena. From a scientific standpoint, interest is driven by the availability of a very robust enzyme, glucose oxidase, which can be used to monitor glucose, as well as the desire to develop model sensors for a wide variety of analytes. Any amperometric glucose sensor or any oxido-reductase enzyme that uses
  • O 2 as a co-substrate and is designed for subcutaneous or intravenous use requires both an outer membrane and an anti- interference membrane.
  • the requirement of two distinct membranes is due to the fundamental nature of the sensor as well as the environment in which the measurement is made.
  • a glucose sensor works according to the following chemical reaction
  • Equation 1 The current measured by the sensor/potentiostat (+0.5 to +0.7 v oxidation at Pt black electrode) is due to the two electrons generated by the oxidation of the H 2 O 2 .
  • the stoichiometry of Equation 1 clearly demonstrates some of the problems with an implantable glucose sensor. If there is excess oxygen for Equation 1, then the H 2 O 2 is stoichiometrically related to the amount of glucose that reacts at the enzyme. In this case, the ultimate current is also proportional to the amount of glucose that reacts with the enzyme.
  • glucose must be the limiting reagent, i.e. the O 2 concentration must be in excess for all potential glucose concentrations. For a number of conditions, this requirement is not easily achieved.
  • glucose concentration in the body of a diabetic patient can vary from 2 to 30 mM (millimoles per liter or 36 to 540 mg/dl), whereas the typical oxygen concentration in the tissue is 0.02 to 0.2 mM (see, Fisher, et al., Biomed. Biochem. Ada. 48:965-971 (1989).
  • This ratio in the body means that the sensor would be running in the Michaelis Menten limited regime and would be very insensitive to small changes in the glucose concentration. This problem has been called the "oxygen deficit problem" . Accordingly, a method or system must be devised to either increase the O 2 in the GOX membrane, decrease the glucose concentration, or devise a sensor that does not use O 2 .
  • Another problem with both the perforated membrane approach and the microporous membrane approach is that the sensor electrodes and the enzyme layer are exposed to body fluids.
  • Body fluids contain proteins that coat the electrodes leading to decreased sensitivity of the sensor and enzymes (proteases) that can digest or degrade the sensor active enzyme.
  • Gough U.S. Patent No. 4,484,987, incorporated herein by reference.
  • the approach uses a combination membrane with discrete domains of a hydrophilic material embedded in a hydrophobic membrane. In this case, the membrane is not homogenous and manufacturing reproducibility is difficult. Physical properties of the membrane are also compromised.
  • Gough U.S. Patent No. 4,890,620, incorporated herein by reference
  • the membrane systems described in the literature as cited above attempt only to circumvent the oxygen deficit problem by reducing the amount of glucose diffusion to the working electrode of the biosensor.
  • the membrane There is a need for the membrane to have physical stability and strength, adhesion to the substrate, processibility (ability to be synthesized/manufactured in reasonable quantities and at reasonable prices), biocompatibility, ability to be cut by laser ablation (or some other large scale processing method), and compatibility with the enzyme as deposited on the sensor.
  • the present invention fulfills these needs and provides other related advantages.
  • compositions which are biocompatible and suitable for coating a biosensor are polymers which are formed into membranes and can be prepared from:
  • hydrophilic polymer which is a hydrophilic diol, a hydrophilic diamine, or a combination thereof
  • the membranes prepared from the above components will have a glucose diffusion coefficient of from about 1 x 10 9 cm 2 /sec to about 200 x 10 9 cm 2 / sec, a water pickup of at least about 25% and a ratio of D oxygen /D g
  • the functional groups present in the siloxane polymer are amino, hydroxyl or carboxylic acid, more preferably amino or hydroxyl groups.
  • the hydrophilic polymer is a poly(ethylene)glycol which is PEG 200, PEG 400 or PEG 600.
  • the diisocyanate is a isophorone diisocyanate, 1 ,6-hexamethylene diisocyanate or 4,4'-methylenebis(cyclohexyl isocyanate) and the chain extender is an alkylene diol, an alkylene diamine, an aminoalkanol or a combinations thereof.
  • the diisocyanate is 1,6-hexamethylene diisocyanate
  • the hydrophilic polymer is PEG 400 or PEG 600 and is present in an amount of about 17 to about 32 mol% (relative to all reactants)
  • the siloxane polymer is aminopropyl polysiloxane having a molecular weight of about 2000 to about 4000 and is present in an amount of about 17 to about 32 mol% (relative to all reactants).
  • the present invention further provides an implantable biosensor for measuring the reaction of an analyte, preferably glucose, and oxygen, the biosensor having a biocompatible membrane as described above.
  • Figure 1 illustrates polymerization reactions of a diisocyanate with a poly(alkylene) glycol or a diamino poly(alkylene oxide) which results in a polyurethane or polyurea, respectively.
  • Figures 2 and 3 provide the structures of certain aliphatic and aromatic diisocyanates which are useful in forming the membranes described below.
  • Figure 4 provides the structures of a number of hydrophilic polymers including poly(alkylene) glycols and diamino poly(alkylene oxides) which are used in polymers described below.
  • Figure 5 provides the structures of certain silicones which are useful in forming the membranes described below.
  • FIGS 6 and 7 provides synthetic procedures for the preparation of some silicone polymers used in the present invention.
  • Figure 8 provides the structures of some chain extenders which are useful in the present compositions. This include aliphatic diols, diamines and alkanolamines and further include some aromatic diols and diamines.
  • Figure 9 is an infrared spectrum of a polyurea composition prepared in accordance with the present invention.
  • Figure 10 illustrates portions of a glucose sensor which can be coated with a membrane of the present invention.
  • Figure 10A is a schematic top view of a glucose sensor having electrodes covered with a polymer composition of the invention.
  • Figure 10B is a sectional side view of a working electrode of the sensor which is covered with layers of an enzyme and a polymer composition of the invention.
  • Figure 11 is a graph showing sensor output in various glucose solutions as a function of time.
  • dl deciliter
  • DEG diethylene glycol
  • DMF dimethyl formamide
  • PBS phosphate buffered saline
  • THF tetrahydrofuran
  • DI deionized
  • PEG poly(ethylene)glycol
  • HDI 1 ,6-hexane diisocyanate (1,6- hexamethylene diisocyanate)
  • TMDI 2,2,4,4-tetramethyl-l ,6-hexane diisocyanate and 2,4,4-trimethyl-l ,6-hexane diisocyanate
  • CHDI 1 ,4-cyclohexane diisocyanate
  • BDI 1 ,4- cyclohexane bis(methylene isocyanate)
  • H 6 XDI 1 ,3-cyclohexane bis(methylene isocyanate) or hexahydro metaxylene diisocyanate
  • IPDI XDI, 1 ,3
  • polyurethane/polyurea refers to a polymer containing urethane linkages, urea linkages or combinations thereof.
  • polymers are formed by combining diisocyanates with alcohols and/or amines.
  • combining isophorone diisocyanate with PEG 600 and aminopropyl polysiloxane under polymerizing conditions provides a polyurethane/polyurea composition having both urethane (carbamate) linkages and urea linkages.
  • glucose sensors intended for in vivo use must also be biocompatible with the body, and they must be able to function in an environment in which acids are present as well as proteins which can interfere with a sensor.
  • the enzyme(s) used in such sensors must be protected from degradation or denaturation, while the elements of such sensors must be protected from molecules which would foul the sensors or their accuracy will decrease over time.
  • the present invention provides a biocompatible membrane formed from a reaction mixture of: (a) a diisocyanate, said diisocyanate comprising about 50 mol% of the reactants in said mixture;
  • hydrophilic polymer which is a member selected from the group consisting of a hydrophilic diol, a hydrophilic diamine and combinations thereof; and (c) a silicone polymer having functional groups at the chain termini.
  • the reaction mixture will contain a chain extender.
  • the membrane formed using the polymerized mixture of the above components will have a glucose diffusion coefficient of from about 1 to about 200 x 10 "9 cm 2 /sec, a water pickup of at least 25 % and a ratio of D oxygen /D glucose of from about 5 to about 200.
  • the polymer used in forming the biocompatible membranes will be a polyurea, a polyurethane or a polyurethane/polyurea combination.
  • Figure 1 illustrates some of the polymerization reactions which result in the compositions of the present invention.
  • the homogeneous membranes of the invention are prepared from biologically acceptable polymers whose hydrophobic/hydrophilic balance can be varied over a wide range to control the ratio of the diffusion coefficient of oxygen to that of glucose, and to match this ratio to the design requirements of electrochemical glucose sensors intended for in vivo use.
  • Such membranes can be prepared by conventional methods by the polymerization of monomers and polymers noted above.
  • the resulting polymers are soluble in solvents such as acetone or ethanol and may be formed as a membrane from solution by dip, spray or spin coating.
  • the diisocyanates which are useful in this aspect of the invention are those which are typically those which are used in the preparation of biocompatible polyurethanes. Such diisocyanates are described in detail in Szycher, SEMINAR ON ADVANCES IN MEDICAL GRADE POLYURETHANES, Technomic Publishing, (1995) and include both aromatic and aliphatic diisocyanates (see Figures 2 and 3). Examples of suitable aromatic diisocyanates include toluene diisocyanate, 4,4'-diphenylmethane diisocyanate, 3, 3 '-dimethyl-4,4'-biphenyl diisocyanate, naphthalene diisocyanate and paraphenylene diisocyanate.
  • Suitable aliphatic diisocyanates include, for example, 1 ,6- hexamethylene diisocyanate (HDI), trimethylhexamethylene diisocyanate (TMDI), trans- 1,4-cyclohexane diisocyanate (CHDI), 1 ,4-cyclohexane bis(methylene isocyanate) (BDI), 1 ,3-cyclohexane bis(methylene isocyanate) (H 6 XDI), isophorone diisocyanate (IPDI) and 4,4'-methylenebis(cyclohexyl isocyanate) (H, 2 MDI).
  • HDI 1 ,6- hexamethylene diisocyanate
  • TMDI trimethylhexamethylene diisocyanate
  • CHDI trans- 1,4-cyclohexane diisocyanate
  • CHDI trans- 1,4-cyclohexane diisocyanate
  • BDI 1 ,4-cyclo
  • the diisocyanate is isophorone diisocyanate, 1 ,6-hexamethylene diisocyanate, or 4,4'- methylenebis(cyclohexyl isocyanate).
  • a number of these diisocyanates are available from commercial sources such as Aldrich Chemical Company (Milwaukee, Wisconsin, USA) or can be readily prepared by standard synthetic methods using literature procedures.
  • the quantity of diisocyanate used in the reaction mixture for the present compositions is typically about 50 moI% relative to the combination of the remaining reactants. More particularly, the quantity of diisocyanate employed in the preparation of the present compositions will be sufficient to provide at least about 100% of the — NCO groups necessary to react with the hydroxyl or amino groups of the remaining reactants.
  • a second reactant used in the preparation of the biocompatible membranes described herein is a hydrophilic polymer.
  • the hydrophilic polymer can be a hydrophilic diol, a hydrophilic diamine or a combination thereof.
  • the hydrophilic diol can be a poly(alkylene)glycol, a polyester-based polyol, or a polycarbonate polyol (see Figure 4).
  • poly(alkylene)glycol refers to polymers of lower alkylene glycols such as poly(ethylene)glycol, poly(propylene)glycol and polytetramethylene ether glycol (PTMEG).
  • polystyrene-based polyol refers to a polymer as depicted in Figure 4 in which the R group is a lower alkylene group such as ethylene, 1,3-propylene, 1,2-propylene, 1,4-butylene, 2,2-dimethyl-l,3-propylene, and the like.
  • R group is a lower alkylene group such as ethylene, 1,3-propylene, 1,2-propylene, 1,4-butylene, 2,2-dimethyl-l,3-propylene, and the like.
  • the diester portion of the polymer can also vary from the six- carbon diacid shown.
  • Figure 4 illustrates an adipic acid component
  • the present invention also contemplates the use of succinic acid esters, glutaric acid esters and the like.
  • polycarbonate polyol refers those polymers having hydroxyl functionality at the chain termini and ether and carbonate functionality within the polymer chain (see Figure 4).
  • the alkyl portion of the polymer will typically be composed of C2 to C4 aliphatic radicals, or in some embodiments, longer chain aliphatic radicals, cycloaliphatic radicals or aromatic radicals.
  • hydrophilic diamines refers to any of the above hydrophilic diols in which the terminal hydroxyl groups have been replaced by reactive amine groups or in which the terminal hydroxyl groups have been derivatized to produce an extended chain having terminal amine groups.
  • a preferred hydrophilic diamine is a "diamino poly (oxy alkylene)" which is poly(alkylene)glycol in which the terminal hydroxyl groups are replaced with amino groups.
  • the term "diamino poly (oxy alkylene” also refers to poly (alky lene)glycols which have aminoalkyl ether groups at the chain termini.
  • a suitable diamino poly(oxyalkylene) is poly(propylene glycol)bis(2-aminopropyl ether).
  • a number of the above polymers can be obtained from Aldrich Chemical Company. Alternatively, literature methods can be employed for their synthesis.
  • the amount of hydrophilic polymer which is used in the present compositions will typically be about 10% to about 80% by mole relative to the diisocyanate which is used. Preferably, the amount is from about 20% to about 60% by mole relative to the diisocyanate. When lower amounts of hydrophilic polymer are used, it is preferable to include a chain extender (see below). Silicone polymers which are useful in the present invention are typically linear, have excellent oxygen permeability and essentially no glucose permeability. Preferably, the silicone polymer is a polydimethylsiloxane having two reactive functional groups (i.e, a functionality of 2).
  • the functional groups can be, for example, hydroxyl groups, amino groups or carboxylic acid groups, but are preferably hydroxyl or amino groups (see Figure 5).
  • combinations of silicone polymers can be used in which a first portion comprises hydroxyl groups and a second portion comprises amino groups.
  • the functional groups are positioned at the chain termini of the silicone polymer.
  • suitable silicone polymers are commercially available from such sources as Dow Chemical Company (Midland, Michigan, USA) and General Electric Company (Silicones Division, Schenectady, New York, USA). Still others can be prepared by general synthetic methods as illustrated in Figures 6 and 7, beginning with commercially available siloxanes (United Chemical Technologies, Bristol, Pennsylvania, USA).
  • the silicone polymers will preferably be those having a molecular weight of from about 400 to about 10,000, more preferably those having a molecular weight of from about 2000 to about 4000.
  • the amount of silicone polymer which is incorporated into the reaction mixture will depend on the desired characteristics of the resulting polymer from which the biocompatible membrane are formed. For those compositions in which a lower glucose penetration is desired, a larger amount of silicone polymer can be employed. Alternatively, for compositions in which a higher glucose penetration is desired, smaller amounts of silicone polymer can be employed.
  • the amount of siloxane polymer will be from 10% to 90% by mole relative to the diisocyanate. Preferably, the amount is from about 20% to 60% by mole relative to the diisocyanate.
  • the reaction mixture for the preparation of biocompatible membranes will also contain a chain extender which is an aliphatic or aromatic diol, an aliphatic or aromatic diamine, alkanolamine, or combinations thereof (see Figure 8).
  • a chain extender which is an aliphatic or aromatic diol, an aliphatic or aromatic diamine, alkanolamine, or combinations thereof.
  • suitable aliphatic chain extenders include ethylene glycol, propylene glycol, 1,4-butanediol, 1,6-hexanediol, ethanolamine, ethylene diamine, butane diamine, 1 ,4-cyclohexanedimethanol.
  • Aromatic chain extenders include, for example, /r ⁇ ra-di(2-hydroxyethoxy)benzene, met ⁇ -di(2-hydroxyethoxy)benzene, Ethacure 100 ® (a mixture of two isomers of 2,4-diamino-3,5-diethyltoluene), Ethacure 300 ® (2,4-diamino- 3,5-di(methylthio)toluene), 3,3'-dichloro-4,4'diaminodiphenylmethane, Polacure ® 740 M (trimethylene glycol bis(pflr ⁇ -aminobenzoate)ester), and methylenedianiline.
  • chain extenders typically provides the resulting biocompatible membrane with additional physical strength, but does not substantially increase the glucose permeability of the polymer.
  • a chain extender is used when lower (i.e., 10-40 mol %) amounts of hydrophilic polymers are used.
  • the chain extender is diethylene glycol which is present in from about 40% to 60% by mole relative to the diisocyanate.
  • Polymerization of the above reactants can be carried out in bulk or in a solvent system. Use of a catalyst is preferred, though not required. Suitable catalysts include dibutyltin bis(2-ethylhexanoate), dibutyltin diacetate, triethylamine and combinations thereof. Preferably dibutyltin bis(2-ethylhexanoate is used as the catalyst.
  • Bulk polymerization is typically carried out at an initial temperature of about 25 °C (ambient temperature) to about 50°C, in order to insure adequate mixing of the reactants. Upon mixing of the reactants, an exotherm is typically observed, with the temperature rising to about 90-120°C.
  • the reaction flask can be heated at from 75°C to 125°C, with 90°C to 100°C being a preferred temperature range. Heating is usually carried out for one to two hours.
  • Solution polymerization can be carried out in a similar manner. Solvents which are suitable for solution polymerization include dimethylformamide, dimethyl sulfoxide, dimethylacetamide, halogenated solvents such as 1,2,3-trichloropropane, and ketones such as 4-methyl-2-pentanone. Preferably, THF is used as the solvent. When polymerization is carried out in a solvent, heating of the reaction mixture is typically carried out for three to four hours.
  • Polymers prepared by bulk polymerization are typically dissolved in dimethylformamide and precipitated from water. Polymers prepared in solvents that are not miscible with water can be isolated by vacuum stripping of the solvent. These polymers are then dissolved in dimethylformamide and precipitated from water. After thoroughly washing with water, the polymers can be dried in vacuo at about 50°C to constant weight.
  • Preparation of the membranes can be completed by dissolving the dried polymer in a suitable solvent and cast a film onto a glass plate.
  • a suitable solvent for casting will typically depend on the particular polymer as well as the volatility of the solvent.
  • the solvent is THF, CHC1 3 , CH 2 C1 2 , DMF or combinations thereof. More preferably, the solvent is THF or DMF/CH 2 C1 2 (2/98 volume %).
  • the resulting membranes are hydrated fully, their thicknesses measured and water pickup is determined.
  • Membranes which are useful in the present invention will typically have a water pickup of about 20 to about 100%, preferably 30 to about 90%, and more preferably 40 to about 80%, by weight.
  • Oxygen and glucose diffusion coefficients can also be determined for the membranes of the present invention. Methods for determining diffusion coefficients are known to those of skill in the art, and examples are provided below.
  • the biocompatible membranes described herein will preferably have a oxygen diffusion coefficient (D 0Iiygen ) of about 0.1 x 10 '6 cm 2 /sec to about 2.0 x 10 '6 cm 2 /sec and a glucose diffusion coefficient (D g i ucose ) of about 1 x 10 9 cm 2 /sec to about 500 x 10 9 cm 2 /sec. More preferably, the glucose diffusion coefficient is about 10 x 10 9 cm 2 /sec to about 200 x 10 9 cm 2 /sec.
  • the discovery underlying the present invention is the use of silicon-containing polymers, such as siloxanes, in the formation of biocompatible membranes.
  • the silicon-containing polymers are used in conjunction with (covalently attached to) hydrophilic polymers for the preparation of membranes in which the movement of analytes and reactive species ⁇ e.g., oxygen and glucose) can be controlled by varying the amounts of each component.
  • the membranes produced from these components are homogeneous and are useful for coating a number of biosensors and devices designed for subcutaneous implantation.
  • Glucose sensors which utilize, for example, glucose oxidase to effect a reaction of glucose and oxygen are known in the art, and are within the skill in the art to fabricate. See, for example, U.S. Patent Nos. 5,165,407, 4,890,620, 5,390,671 and 5,391 ,250, the disclosures of each being incorporated herein by reference.
  • the present invention depends not on the configuration of the biosensor, but rather on the use of the inventive membranes to cover or encapsulate the sensor elements.
  • the biocompatible membranes of the present invention are useful with a variety of biosensors for which it is advantageous to control diffusion of the analytes/reactants to the sensing elements.
  • biosensors are well known in the art. For example, other sensors for monitoring glucose concentration of diabetics are described in Shichiri, et al., : "In Vivo Characteristics of Needle-Type Glucose Sensor- Measurements of Subcutaneous Glucose Concentrations in Human
  • (a) Membrane Preparation Membranes were prepared by casting films from a suitable solvent onto glass plates using a parallel arm Gardner knife (Gardner Labs). The solvent chosen will depend on the particular chemical structure of the polymer. Typically, THF or DMF/CH 2 C1 2 (2/98 vol %) are used although chloroform is also useful as it is readily volatile. After removal of the solvent, the dried membranes were hydrated with deionized water for 30-60 minutes. The membranes were then removed and transferred to a Mylar ® support sheet. Wet film thicknesses were measured with a micrometer before removal from the support. Films were also cast from solution onto filtration membranes of known thickness. For the measurements provided below, it was assumed that the membrane material completely filled the pores of the filtration membranes and that the thickness of the filtration media is the thickness of the membrane. (b) Diffusion constants
  • the diffusion coefficient is a physical property of both the analyte of interest and the material in which it is diffusing.
  • D is a property of the system under evaluation.
  • Oxygen diffusion constants (D 0 ) were determined by securing the membrane with two rubber gaskets between the two halves of a diffusion cell maintained at 37 °C, and clamping the two halves together.
  • Each side of the cell was filled with phosphate buffered saline (PBS, 0.15 M NaCl, 0.05 M phosphate, pH 7.4). One side was saturated with HPLC grade helium while the other side was saturated with room air (assumed 20% O 2 ).
  • a calibrated oxygen electrode (Microelectrodes, Inc.) was placed in each cell. The oxygen electrode outputs were connected to a microcomputer-controlled data acquisition system and the oxygen concentration from both cells was recorded as a function of time. The curves of concentration vs. time were plotted and the diffusion coefficients were calculated using the entire curve. Curve fits generally had correlation coefficients (R 2 ) of greater than 0.95.
  • Glucose diffusion constants were determined as above except that one half of the cell was filled with phosphate buffered saline containing 400 mg/dl of glucose. The concentration of glucose in each half of the cell was measured at 5 minute intervals until equilibrium was achieved using a YSI glucose analyzer. As above, the curves of concentration vs. time were plotted and the diffusion coefficient was calculated.
  • This example illustrates a bulk polymerization method of polymer formation carried out with isophorone diisocyanate, PEG 600, diethylene glycol and aminopropyl terminated polydimethyl siloxane.
  • Isophorone diisocyanate (4.44 g, 20 mmol, 100 mol%) was dried over molecular sieves and transferred to a 100 mL round bottom flask fitted with a nitrogen purge line and a reflux condenser.
  • PEG 600 (2.40 g, 4.0 mmol, 20 mol%), diethylene glycol (1.06 g, 10 mmol, 50 mol%) and aminopropyl terminated polydimethylsiloxane (15 g, 6.0 mmol, 30 mol%, based on a 2500 average molecular weight) were added to the flask. Heating was initiated using a heating mantle until a temperature of 50 °C was obtained. Dibutyltin bis(2-ethylhexanoate) (15 mg) was added and the temperature increased to about 95 °C. The solution was continuously stirred at a temperature of 65 °C for a period of 4 hr during which time the mixture became increasingly viscous.
  • This example illustrates a solution polymerization method using 1,6- hexamethylene diisocyanate, PEG 200 and aminopropyl terminated polydimethylsiloxane.
  • Dried 1 ,6-hexamethylene diisocyanate (1.34 g, 8 mmol, 100 mol%) was added to a 100 mL 3-neck flask containing 20 mL of dry THF.
  • PEG 200 (0.8 g, 4.0 mmol, 50 mol%) was added with stirring followed by addition of aminopropyl terminated polydimethylsiloxane (10 g, 4.0 mmol, 50 mol%).
  • the resulting solution was warmed to 50 °C and dibutyltin bis(2-ethylhexanoate) (about 15 mg) was added. After an initial temperature rise to 83 °C, the mixture was warmed and held at 70°C for 12 hr, during which time the mixture had become very viscous. After cooling, the mixture was poured into 3 L of rapidly stirring DI water. The precipitated polymer was collected, washed with DI water (3X), torn into small pieces and dried at 50°C until a constant weight was obtained.
  • a membrane was prepared as described above. An infrared spectrum of the product was obtained and is reproduced in Figure 9, exhibiting the expected absorbance bands (cm 1 ).
  • Table 2 provides certain physical and chemical properties of the polymers provided above.
  • This example illustrates the evaluation of a membrane-coated biosensor constructed according to the present invention.
  • a membrane prepared from the polymer identified as 3 above was found to have excellent mechanical properties as well as appropriate oxygen and glucose diffusivities.
  • the membrane was evaluated using a prototype glucose sensor illustrated in Figure 10A.
  • a sensor 10 was constructed having a reference electrode 12, a working electrode 14, and a counter electrode 16 deposited on a polymeric sheet 19.
  • a series of bonding pads 18 complete the sensor 10.
  • the working electrode 14 was covered with a layer 20 of the enzyme glucose oxidase and the entire electrode array was coated with a layer 22 of the polymer 3 by dip coating two times from a 5 wt% solution of the polymer in THF.
  • the sensor was connected to a commercial potentiostat (BAS Instruments, not shown) and operated with a potential of +0.6 volts between the working electrode and the reference electrode.
  • Glucose response is shown in Figure 11. As seen in Figure 11 , the response of the electrode system is linear over the physiological glucose range, suggesting relative independence of local O 2 concentration. All of the other polymers tested showed similar behavior to the polymer identified as 3 and are acceptable as membranes for biosensor applications.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Polyurethanes Or Polyureas (AREA)

Abstract

Cette invention se rapporte à des membranes biocompatibles destinées à des biocapteurs. Lesdites membranes sont composées de polymères qui peuvent être préparés à partir (a) d'un diisocyanate, (b) d'un polymère hydrophile, (c) d'un polymère de siloxane possédant des groupes fonctionnels au niveau de ses terminaisons de chaînes, et éventuellement (c) d'un allongeur de chaîne.
EP96933898A 1996-09-26 1996-09-26 Membranes biocompatibles contenant des silicones Withdrawn EP0870191A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US1996/015386 WO1998013685A1 (fr) 1996-09-26 1996-09-26 Membranes biocompatibles contenant des silicones
CA002238005A CA2238005C (fr) 1996-09-26 1996-09-26 Membranes biocompatibles contenant des silicones

Publications (1)

Publication Number Publication Date
EP0870191A1 true EP0870191A1 (fr) 1998-10-14

Family

ID=25680215

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96933898A Withdrawn EP0870191A1 (fr) 1996-09-26 1996-09-26 Membranes biocompatibles contenant des silicones

Country Status (3)

Country Link
EP (1) EP0870191A1 (fr)
AU (1) AU7245796A (fr)
WO (1) WO1998013685A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003527599A (ja) 2000-03-17 2003-09-16 エフ．ホフマン−ラ ロシュ アーゲー 埋め込み型アナライトセンサー
US6642015B2 (en) 2000-12-29 2003-11-04 Minimed Inc. Hydrophilic polymeric material for coating biosensors
US7813780B2 (en) * 2005-12-13 2010-10-12 Medtronic Minimed, Inc. Biosensors and methods for making and using them
US7311812B2 (en) 2003-05-30 2007-12-25 Abbott Laboratories Biosensor
US8660628B2 (en) 2009-12-21 2014-02-25 Medtronic Minimed, Inc. Analyte sensors comprising blended membrane compositions and methods for making and using them
US11179078B2 (en) 2016-06-06 2021-11-23 Medtronic Minimed, Inc. Polycarbonate urea/urethane polymers for use with analyte sensors
WO2019222499A1 (fr) 2018-05-16 2019-11-21 Medtronic Minimed, Inc. Membrane de limitation de glucose thermiquement stable pour capteurs de glucose
US11998330B2 (en) 2021-01-29 2024-06-04 Medtronic Minimed, Inc. Interference rejection membranes useful with analyte sensors
US12201421B2 (en) 2021-10-08 2025-01-21 Medtronic Minimed, Inc. Immunosuppressant releasing coatings
US20240023849A1 (en) 2022-07-20 2024-01-25 Medtronic Minimed, Inc. Acrylate hydrogel membrane for dual function of diffusion limiting membrane as well as attenuation to the foreign body response

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4584337A (en) * 1984-12-18 1986-04-22 Dow Corning Corporation Aqueous emulsions containing hydrophilic silicone-organic copolymers
US5128408A (en) * 1987-11-16 1992-07-07 Toyo Boseki Kabushiki Kaisha Gas-permeable material with excellent compatibility with blood
JPH02298855A (ja) * 1989-03-20 1990-12-11 Assoc Univ Inc 固定化酵素とレドックス重合体を用いた電気化学的バイオセンサー
US5322063A (en) * 1991-10-04 1994-06-21 Eli Lilly And Company Hydrophilic polyurethane membranes for electrochemical glucose sensors
DE69526366T2 (de) * 1994-11-14 2002-11-14 Bayer Corp., East Walpole Zufallsverteilt segmentierte thermoplastische polyurethane als matrix zur elektrochemischen analyse von zweiwertigen kalziumionen
US5882494A (en) * 1995-03-27 1999-03-16 Minimed, Inc. Polyurethane/polyurea compositions containing silicone for biosensor membranes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9813685A1 *

Also Published As

Publication number Publication date
WO1998013685A1 (fr) 1998-04-02
AU7245796A (en) 1998-04-17

Similar Documents

Publication Publication Date Title
US5777060A (en) Silicon-containing biocompatible membranes
US6784274B2 (en) Hydrophilic, swellable coatings for biosensors
US6642015B2 (en) Hydrophilic polymeric material for coating biosensors
US7687586B2 (en) Biosensor membrane material
US8053018B2 (en) Techniques to improve polyurethane membranes for implantable glucose sensors
AU658450B2 (en) Hydrophilic polyurethane membranes for electrochemical glucose sensors
EP1629028B1 (fr) Matiere de membrane structurellement robuste permselective
CA1323151C (fr) Membranes a base de polyetherurethanne reticule utilisees dans des dispositifs de detection des electrolytes du sang
WO2006018425A2 (fr) Membrane semi-permeable multiphase biocompatible pour biocapteurs
WO1998013685A1 (fr) Membranes biocompatibles contenant des silicones
CA2238005C (fr) Membranes biocompatibles contenant des silicones
JP4098364B2 (ja) 珪素含有生体適合性膜
CN113493558A (zh) 植入式生物传感器用三嵌段共聚物及其应用和制备方法
JP2000500691A (ja) 珪素含有生体適合性膜

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980615

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MINIMED INC.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MEDTRONIC MINIMED, INC.

17Q First examination report despatched

Effective date: 20021210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030621